Helgestad Ole Kristian Lerche, Josiassen Jakob, Hassager Christian, Jensen Lisette Okkels, Holmvang Lene, Udesen Nanna Louise Junker, Schmidt Henrik, Berg Ravn Hanne, Moller Jacob Eifer
Department of Cardiology, Odense Universitetshospital, Odense, Denmark.
Emergency Medicine, Regional Hospital Randers, Randers, Midtjylland, Denmark.
Open Heart. 2020 Mar 4;7(1):e001214. doi: 10.1136/openhrt-2019-001214. eCollection 2020.
To describe the contemporary trends in the use of mechanical circulatory support (MCS) in patients with acute myocardial infarction and cardiogenic shock (AMICS). To evaluate survival benefit with early application of intra-aortic balloon pump (IABP) or Impella CP.
A cohort study of all consecutive patients with AMICS undergoing percutaneous coronary intervention (PCI) <24 hours of symptom onset (early PCI) in southeastern Denmark from 2010 to 2017. A matched case-control study comparing 30-day mortality between patients receiving early-IABP or early-Impella CP and their respective control group. Controls were matched on age, left ventricular ejection fraction, arterial lactate, estimated glomerular filtration rate and cardiac arrest before PCI. Early-IABP/Impella CP was defined as applied before PCI if shock developed pre-PCI, or immediately after PCI if shock developed during PCI.
903 patients with AMICS undergoing early PCI were identified. Use of MCS decreased from 50% in 2010 to 25% in 2017, p for trend of <0.001. The IABP was abandoned in 2012 and replaced mostly by Impella CP. Patients receiving MCS in 2013-2017 had more compromised haemodynamics compared with patients receiving MCS in 2010-2012. 40 patients received early IABP, and 40 patients received early Impella CP. Only the group receiving early Impella CP was associated with lower 30-day mortality compared with their matched control group (30-day mortality 40% vs 77.5%, of<0.001).
Use of MCS decreased by 50% from 2010 to 2017. Patients receiving MCS had more compromised haemodynamics in recent years. Early application of Impella CP was associated with reduced 30-day mortality compared with a matched control group.
描述急性心肌梗死合并心源性休克(AMICS)患者使用机械循环支持(MCS)的当代趋势。评估早期应用主动脉内球囊反搏(IABP)或Impella CP的生存获益。
对2010年至2017年丹麦东南部所有在症状发作后<24小时接受经皮冠状动脉介入治疗(PCI)的连续性AMICS患者进行队列研究。一项匹配病例对照研究,比较接受早期IABP或早期Impella CP的患者与其各自对照组的30天死亡率。对照组在年龄、左心室射血分数、动脉乳酸、估计肾小球滤过率和PCI前心脏骤停方面进行匹配。早期IABP/Impella CP定义为:如果在PCI前发生休克,则在PCI前应用;如果在PCI期间发生休克,则在PCI后立即应用。
共识别出903例接受早期PCI的AMICS患者。MCS的使用从2010年的50%降至2017年的25%,趋势p<0.001。IABP在2012年被弃用,主要被Impella CP取代。与2010 - 2012年接受MCS的患者相比,2013 - 2017年接受MCS的患者血流动力学受损更严重。40例患者接受早期IABP,40例患者接受早期Impella CP。与匹配对照组相比,仅接受早期Impella CP的组30天死亡率较低(30天死亡率40%对77.5%,p<0.001)。
2010年至2017年,MCS的使用减少了50%。近年来接受MCS的患者血流动力学受损更严重。与匹配对照组相比,早期应用Impella CP与30天死亡率降低相关。